Actively Recruiting
Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts
Led by Labo'Life · Updated on 2024-10-30
162
Participants Needed
18
Research Sites
369 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Human papillomavirus (HPV) infection is very common, as most people will experience infection during their lifetime. The most common manifestation of HPV infection is common warts. Common warts may appear at any age. Conventional treatments can be used to treat warts and they are based on two mechanisms: stimulation of cellular immunity against HPVs or destruction of the lesion. These treatments are based on the location of the wart and the degree of the symptoms. No specific antiviral therapy is available to cure warts and today, there is no treatment that allows the definitive eradication of the virus. The 2LVERU® has been available for more than 20 years, and has received a marketing authorization in Belgium by the Federal Agency for Medicines and Health Products (FAMHP). It is used as an immune regulator in the treatment of common warts (verruca vulgaris), flat warts (verruca plana) or plantar warts (verruca plantaris) caused by Human Papillomavirus. Since 2LVERU® has been made available, clinical observational data collected on treated patients have shown the beneficial effect on the disappearance of warts. The purpose of this placebo-controlled, randomized, double-blind trial is the comparison of the efficacy of the treatment on the disappearance of warts at the end of treatment (6-month visit) between the 2LVERU® JUNIOR and 2LVERU® versus the placebo group.
CONDITIONS
Official Title
Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 3 years and older
- Patients with common warts, plantar warts, or flat warts
- Patients (or their parents) able to understand and follow study requirements
- Signed informed consent by the patient or parent/guardian
You will not qualify if you...
- Patients treated for warts in the previous 2 months
- Patients who had homeopathic treatment in the previous 2 months
- Patients on immunosuppressive treatment
- Patients who had immunotherapy or micro-immunotherapy in the last 6 months
- Patients with known lactose intolerance
- Pregnant or breastfeeding women
- Patients who participated in another clinical study in the last 2 months
- Patients or parents not motivated to complete the study or likely to move/travel before study ends
- Patients with severe immunodeficiency needing long-term treatment, chemotherapy, or radiotherapy
- Patients taking specific homeopathic or phytotherapy treatments
- Patients addicted to or using recreational drugs
- Patients under guardianship or curatorship
- Patients with serious kidney or lung problems, transplant recipients, HIV/AIDS, or terminal cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 18 locations
1
Private Practice
Arlon, Belgium, 6700
Withdrawn
2
Clinique Saint-Luc (Bouge)
Bouge, Belgium, 5004
Actively Recruiting
3
Private Practice
Brussels, Belgium, 1020
Terminated
4
Private Practice
Écaussinnes-d'Enghien, Belgium, 7190
Terminated
5
Private Practice
Fontaine l'Êveque, Belgium, 6140
Suspended
6
Private Practice
Ghent, Belgium, 9942
Actively Recruiting
7
Private Practice
Gozée, Belgium, 6534
Terminated
8
Private Practice
Hamme-Mille, Belgium, 1320
Actively Recruiting
9
Private Practice
Juprelle, Belgium, 4450
Withdrawn
10
Private Practice
Mons, Belgium, 7000
Withdrawn
11
Private Practice
Namur, Belgium, 5000
Actively Recruiting
12
Private Practice
Namur, Belgium, 5000
Withdrawn
13
Private Practice
Oisquercq, Belgium, 1480
Terminated
14
Private Practice
Plancenoit, Belgium, 1380
Withdrawn
15
Private Practice
Quiévrain, Belgium, 7380
Withdrawn
16
Private Practice
Saint-Symphorien, Belgium, 7030
Actively Recruiting
17
Private Practice
Seneffe, Belgium, 7180
Actively Recruiting
18
Private Practice
Wavre, Belgium, 1300
Actively Recruiting
Research Team
C
Charlotte Bolle
CONTACT
L
Laura FERTE
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here